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bine. LIF activates a unique set of downstream pathways,
distinct from IL-6 and other members of this family of
cytokines. This pathway may account for K-Ras’ unique
ability to promote stem-ness. The existence of a new
effector pathway speciﬁc for KRAS therefore offers new
opportunities for therapeutic intervention.
Immunomodulatory effects of
radiotherapy: Magical effects of the
healing beam?Arta M. Monjazeb UC Davis Comprehensive
Cancer Center, Sacramento, CAImmunotherapy is changing the management of meta-
static lung cancer. Checkpoint inhibitors have demon-
strated promising response in non-small cell lung cancer
and are emerging as amongst the most efﬁcacious anti-
cancer agents ever discovered. Checkpoint inhibitors are
aimed at reversing mechanisms of T-cell suppression by
blocking signaling through regulatory T-cell co-receptors
(e.g. CTLA-4 or PD-1) or blocking T-cell suppressive
enzymes (e.g. Indolamine 2,3 Dioxgenase (IDO)). These
therapies can achieve durable long-term remissions,
however, most patients fail to respond, and some can
experience signiﬁcant immune-mediated toxicities (1-3).
Combinatorial strategies employing immunotherapy and
standard-of-care therapies may increase the efﬁcacy of
immunotherapy and extend its beneﬁt to a larger
proportion of patients. Little data is available on how
best to achieve this goal.
Radiotherapy (RT) is an ideal candidate for combinatorial
immunotherapy strategies. In addition to debulking tumor
and releasing tumor antigens, RT has well-established
immunomodulatory effects (4). These interdependent and
overlapping effects include increasing homing and effector
function of tumor inﬁltrating lymphocytes (TILs) including
T-cells (5) and natural killer (NK) cells (6), increasing the
diversity of the T-cell response (7), destruction of
immunosuppressive cells in the tumor microenvironment
(8), induction of immunogenic cell death (9,10), increased
dendritic cell (DC) trafﬁcking and presentation of tumor
antigen (11), and upregulation of immunogenic cell surface
receptors (12) and stress ligands (6). Additionally our
recent data demonstrate that RT can induce chemokines
such as CCL3, 4, and 5 and the critical nature of these
chemokines to an anti-tumor immune response and the
effectiveness of checkpoint blockade immunotherapy has
recently been highlighted (13). The immunomodulatory
effects of radiotherapy are complex and some of these
effects can be suppressive such as induction of TGF-beta
(14), accumulation of immunosuppressive cells (15),
upregulation of PD-L1 (16), and upregulation of IDO.Clinical reports conﬁrm the safety and efﬁcacy of multi-
modality strategies employing RT and CpG or IL-2 immu-
notherapy (17,18). There is also data to suggest synergy
between RT and checkpoint inhibition (16,19,20). Dozens
of clinical trials testing such combinatorial strategies are
underway with countless others in preparation, which
will together likely accrue thousands of patients. There is
considerable variability in “standard-of-care” RT regimens
and combinatorial strategies could employ a wide variety
of dose/fractionation regimens, sequencing/timing
regimens, and even RT quality (i.e. photons vs. protons).
There is limited mechanistic data available to guide how
to best combine these modalities (21,22). These variables
can substantially alter the efﬁcacy of combined RT +
immunotherapy strategies. A framework for
appropriately combining these therapies is needed and
will have an immediate impact on patient care. It is
possible that different immunotherapies and different
tumors will behave differently in response to these RT
variables. The mechanistic immune effects of RT and
immunotherapy are complex. Identifying the best
strategies to combine these immune effects will likely be
similarly complex.
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Sox2 cooperates with Lkb1 loss to
promote squamous cell lung cancerAnandaroop Mukhopadhyay,
Gurkan Mollaoglu, Benjamin L. Witt,
Trudy G. Oliver University of Utah, Salt Lake City, UT
Squamous cell carcinoma (SCC) of the lung is the second
most common subtype of lung cancer with limited
treatment options and a poor survival rate. Until
recently, mouse models of SCC have been limited. Using
lentiviral delivery of Sox2 to the mouse lung, we testedthe ability of Sox2 to promote tumorigenesis in multiple
tumor suppressor backgrounds. Expression of Sox2
speciﬁcally cooperates with loss of Lkb1 to promote
squamous lung tumors. Importantly, Sox2 expression
and mTOR pathway activation frequently co-occur in
human squamous tumors. Mouse squamous tumors
exhibit characteristic histopathology and biomarker
expression similar to human SCC. Murine SCCs also
mimic human SCCs by activation of therapeutically
relevant pathways including STAT and mTOR. We show
that Sox2 expression is sufﬁcient to induce phosphory-
lated Stat3 in vitro (Mukhopadhyay et al, Cell Reports,
2014). An inducible genetic model of Sox2 expression
and Lkb1 have been generated and are being used to
interrogate the cell of origin for squamous cell lung
cancer. In addition, Sox2-driven tumors exhibit innate
and adaptive immune cell inﬁltration, similar to the
recent PTENﬂ/ﬂLkb1ﬂ/ﬂ model of SCC. These models
may be useful to study immunotherapies and their
mechanism of action, and to test the contribution of
additional driver alterations in SCC.
Proximalization therapy for KRas
mutant adenocarcinomaMark Onaitis Duke University, Durham, NC
KRAS activating mutations are common in lung adeno-
carcinoma and are currently not able to be directly tar-
geted. These are most likely early mutations in the
adenoma-adenocarcinoma sequence and may be present
in phenotypically normal lung. Thus, targeted therapy
would be useful in early stage and/or screened patients.
In order to begin to develop agents targeting these early
lesions, we have used cell lineage speciﬁc CreER mouse
models to analyze cell-of-origin in the mouse lung.
When KrasG12D is induced in various cells throughout
the respiratory epithelium, Type II cells are the primary
cell-of-origin of lung adenocarcinoma. To delve into
mechanism, using gain and loss of function genetic
models, we discovered that low Sox2 expression with
resulting active Notch signaling dictate the ability of
Type II cells to proliferate and progress into adenocarci-
noma upon KrasG12D activation. Because low Sox2 and
high Notch expression characterize a distal lung epithe-
lial progenitor state, we hypothesized that Kras activa-
tion leads to dedifferentiation of Type II cells. We
demonstrated that Kras activation in Type II cells leads
to Spc+Rage+ bipotent progenitor-like cells that also ex-
press speciﬁc the lung embryonic development markers
Sox9 and Ezh2. Next, we use a mouse genetic approach
to show that this dedifferentiation requires Notch
signaling. Additionally, Sox2 upregulation genetically
and chemically profound inhibit KrasG12D-induced
